Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics –

– Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, and Invus –

Read more at globenewswire.com